Try the modernized beta website. Learn more about the modernization effort.
Working… Menu

A Study of IMR-687 in Subjects With Sickle Cell Disease

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. Identifier: NCT04474314
Recruitment Status : Terminated (A recently conducted Interim analysis of IMR-SCD-301 demonstrated that while IMR-687 was generally well-tolerated, it failed to meet its primary efficacy endpoint. So, the sponsor has decided to discontinue this study.)
First Posted : July 16, 2020
Last Update Posted : May 13, 2022
Information provided by (Responsible Party):
Imara, Inc.

No Study Results Posted on for this Study
Recruitment Status : Terminated
Actual Primary Completion Date : March 2, 2022
Actual Study Completion Date : May 4, 2022
Submission Cycle Results Submitted to Results Returned after Quality Control Review
1 June 8, 2022